(Q34758388)

4 August 2017

1 reference

title

Infliximab for the treatment of rheumatoid arthritis (English)

1 reference

4 August 2017

1 reference

7

P Tugwell

1 reference

4 August 2017

B Blumenauer

1

1 reference

4 August 2017

M Judd

2

1 reference

4 August 2017

G Wells

3

1 reference

4 August 2017

A Burls

4

1 reference

4 August 2017

A Cranney

5

1 reference

4 August 2017

M Hochberg

6

1 reference

4 August 2017

1 January 2002

1 reference

Cochrane Database of Systematic Reviews

4 August 2017

1 reference

4 August 2017

3

1 reference

4 August 2017

CD003785

1 reference

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

4 August 2017

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003785

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003785

Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003785

Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003785

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003785

Suppression of fever and the acute-phase response in a patient with juvenile chronic arthritis treated with monoclonal antibody to tumour necrosis factor-alpha (cA2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003785

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003785

The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003785

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003785

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003785

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003785

10.1002/14651858.CD003785

21 January 2018

Identifiers

DOI

1 reference

4 August 2017

1 reference